Pharmacogenetics and the print media: what is the public told?

Basima Almomani, Ahmed F. Hawwa, Nicola A. Goodfellow, Jeffrey S. Millership, James C. McElnay*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Pharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals. The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised medicine by the UK newsprint media.

Methods: The LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21%) of newspaper articles to establish the inter-rater reliability of coding.

Results: Of the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001). The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer, cardiovascular disease and CNS diseases. Only 13% of newspaper articles that cited a specific scientific study mentioned this link in the article. There was a positive correlation between the size of the article and both the number of benefits and risks stated (P < 0.01).

Conclusion: More comprehensive coverage of the area of personalised medicine within the print media is needed to inform public debate on the inclusion of pharmacogentic testing in routine practice.

Original languageEnglish
Article number32
Number of pages10
JournalBMC Medical Genetics
Volume16
Issue number1
DOIs
Publication statusPublished - 9 May 2015

Fingerprint

Newspapers
Pharmacogenetics
Precision Medicine
Central Nervous System Diseases
Pharmaceutical Preparations
Cardiovascular Diseases
Research Personnel
Databases
Genes
Neoplasms
Pharmacogenomic Testing
Therapeutics

Bibliographical note

© 2015 Almomani et al.; licensee BioMed Central.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated

Keywords

  • CNS
  • media
  • newspapers
  • pharmacogenetics

Cite this

Almomani, B., Hawwa, A. F., Goodfellow, N. A., Millership, J. S., & McElnay, J. C. (2015). Pharmacogenetics and the print media: what is the public told? BMC Medical Genetics, 16(1), [32]. https://doi.org/10.1186/s12881-015-0172-3
Almomani, Basima ; Hawwa, Ahmed F. ; Goodfellow, Nicola A. ; Millership, Jeffrey S. ; McElnay, James C. / Pharmacogenetics and the print media : what is the public told?. In: BMC Medical Genetics. 2015 ; Vol. 16, No. 1.
@article{a73abc15fdbb48ae8b2da4c6e002c7eb,
title = "Pharmacogenetics and the print media: what is the public told?",
abstract = "Background: Pharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals. The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised medicine by the UK newsprint media. Methods: The LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21{\%}) of newspaper articles to establish the inter-rater reliability of coding. Results: Of the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001). The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer, cardiovascular disease and CNS diseases. Only 13{\%} of newspaper articles that cited a specific scientific study mentioned this link in the article. There was a positive correlation between the size of the article and both the number of benefits and risks stated (P < 0.01). Conclusion: More comprehensive coverage of the area of personalised medicine within the print media is needed to inform public debate on the inclusion of pharmacogentic testing in routine practice.",
keywords = "CNS, media, newspapers, pharmacogenetics",
author = "Basima Almomani and Hawwa, {Ahmed F.} and Goodfellow, {Nicola A.} and Millership, {Jeffrey S.} and McElnay, {James C.}",
note = "{\circledC} 2015 Almomani et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated",
year = "2015",
month = "5",
day = "9",
doi = "10.1186/s12881-015-0172-3",
language = "English",
volume = "16",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",
number = "1",

}

Almomani, B, Hawwa, AF, Goodfellow, NA, Millership, JS & McElnay, JC 2015, 'Pharmacogenetics and the print media: what is the public told?', BMC Medical Genetics, vol. 16, no. 1, 32. https://doi.org/10.1186/s12881-015-0172-3

Pharmacogenetics and the print media : what is the public told? / Almomani, Basima; Hawwa, Ahmed F.; Goodfellow, Nicola A.; Millership, Jeffrey S.; McElnay, James C.

In: BMC Medical Genetics, Vol. 16, No. 1, 32, 09.05.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacogenetics and the print media

T2 - what is the public told?

AU - Almomani, Basima

AU - Hawwa, Ahmed F.

AU - Goodfellow, Nicola A.

AU - Millership, Jeffrey S.

AU - McElnay, James C.

N1 - © 2015 Almomani et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated

PY - 2015/5/9

Y1 - 2015/5/9

N2 - Background: Pharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals. The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised medicine by the UK newsprint media. Methods: The LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21%) of newspaper articles to establish the inter-rater reliability of coding. Results: Of the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001). The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer, cardiovascular disease and CNS diseases. Only 13% of newspaper articles that cited a specific scientific study mentioned this link in the article. There was a positive correlation between the size of the article and both the number of benefits and risks stated (P < 0.01). Conclusion: More comprehensive coverage of the area of personalised medicine within the print media is needed to inform public debate on the inclusion of pharmacogentic testing in routine practice.

AB - Background: Pharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals. The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised medicine by the UK newsprint media. Methods: The LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21%) of newspaper articles to establish the inter-rater reliability of coding. Results: Of the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001). The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer, cardiovascular disease and CNS diseases. Only 13% of newspaper articles that cited a specific scientific study mentioned this link in the article. There was a positive correlation between the size of the article and both the number of benefits and risks stated (P < 0.01). Conclusion: More comprehensive coverage of the area of personalised medicine within the print media is needed to inform public debate on the inclusion of pharmacogentic testing in routine practice.

KW - CNS

KW - media

KW - newspapers

KW - pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84929147749&partnerID=8YFLogxK

U2 - 10.1186/s12881-015-0172-3

DO - 10.1186/s12881-015-0172-3

M3 - Article

AN - SCOPUS:84929147749

VL - 16

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

IS - 1

M1 - 32

ER -

Almomani B, Hawwa AF, Goodfellow NA, Millership JS, McElnay JC. Pharmacogenetics and the print media: what is the public told? BMC Medical Genetics. 2015 May 9;16(1). 32. https://doi.org/10.1186/s12881-015-0172-3